Pulmocide calls curtains on phase 3 antifungal trial over low response, higher mortality rate
Pulmocide calls curtains on phase 3 antifungal trial over low response, higher mortality rate
Body unavailable. Use the original source.
Pulmocide calls curtains on phase 3 antifungal trial over low response, higher mortality rate
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.